Navigation Links
Forge Therapeutics Announces Novel Antibiotic Presentation at the American Society of Microbiology Conference on Antibacterial Development
Date:12/12/2016

SAN DIEGO, Dec. 12, 2016 /PRNewswire/ -- Forge Therapeutics, Inc. announced today that new preclinical data on its novel class of antibiotic targeting LpxC for treating infections by Gram-negative drug resistant bacteria will be presented at the American Society of Microbiology Conference held in Washington, DC from December 11-14, 2016.

Presentation details:


Conference Title:

ASM Conference on Antibacterial DevelopmentPoster presentation:

Monday, December 12 from 7:00pm to 8:30pmPoster title:

#35 Antimicrobial activity of non-hydroxamate LpxC inhibitorsConference location:

Omni Shoreham Hotel
2500 Calvert Street, NM,
Washington, DC 20008

Conference website:   http://conferences.asm.org/index.php/upcoming-conferences/asm-conference-on-antibacterial-development

About LpxC
Drug resistant Gram-negative bacteria are regarded as an extremely dangerous public health threat, therefore, novel antibiotics targeting Gram-negative bacteria are desperately needed. LpxC is a highly sought after target only found in Gram-negative bacteria.  Forge has discovered novel small molecule inhibitors of LpxC that are potent in vitro, efficacious and tolerated in vivo, and effective against drug resistance mechanisms including mcr-1, KPC, and NDM.  

About Forge Therapeutics, Inc.
Forge Therapeutics, Inc. ("Forge") is a biotechnology start-up that leverages its novel chemistry platform to develop small molecule inhibitors to target metalloproteins.  Metalloproteins are proteins that require metal ions for their biological function and make up over 1/3 of the proteins in the human body.  Forge uses a proprietary approach comprised of molecular modeling for rational drug design along with fundamental knowledge and expertise in bioinorganic chemistry to target metalloproteins.  The name Forge Therapeutics comes from two definitions for forge: to manipulate (inhibit) a metal object (metalloprotein) and to move forward steadily with a purpose (the Forge team).  Forge Therapeutics, Inc., maintains its headquarters in San Diego, California.  To learn more please visit www.ForgeTherapeutics.com.

Contact:
Info@ForgeTherapeutics.com

Logo - http://photos.prnewswire.com/prnh/20150807/256906LOGO

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/forge-therapeutics-announces-novel-antibiotic-presentation-at-the-american-society-of-microbiology-conference-on-antibacterial-development-300376235.html


'/>"/>
SOURCE Forge Therapeutics, Inc.
Copyright©2016 PR Newswire.
All rights reserved


Related biology technology :

1. Don't Forget the Payer in Your Digital Strategy: What Payers Need and Want from Pharma
2. Tor/Forge Launches THE CURE, a Riveting Thriller in the Tradition of Michael Crichton, by the New York Times Bestselling Author of WIRED.
3. Never forget a face
4. Bynder and HubCast Forge Global Partnership for Transformative “Concept to Delivery” Solution
5. Genedata and IntelliCyt Forge Alliance to Transform Cell-based Screening in Drug Discovery
6. Forge Therapeutics Enters Into a Pilot Study with Janssen Research & Development, LLC, to Discover Novel Metalloprotein Inhibitors
7. Forge Therapeutics Co-Founder to Present at the 250th American Chemical Society National Meeting
8. Forge Therapeutics Scientific Co-Founder Bestowed Prestigious National Chemistry Award
9. PointCross Life Sciences And Smithers Avanza Forge Strategic Partnership For SEND Solutions
10. Childhood Leukemias Forged by Different Evolutionary Forces than in Older Adults
11. Peptide Therapeutics Market is Expected to Reach USD 25.4 Billion Globally in 2018: Transparency Market Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/15/2017)...  Trianni, Inc. („TRIANNI") gab heute bekannt, man ... über die Verwendung der The Trianni Mouse unterschrieben, ... Entdeckung monoklonaler Antikörper. Die Trianni Plattform ... das Janssen den Zugang zu einer ... für die schelle Isolierung vollständig menschlicher Therapeutika optimiert ...
(Date:2/15/2017)... Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), today announced financial ... full year ended December 31, 2016. ... we continued to demonstrate strong growth in our ... said Mihael H. Polymeropoulos, M.D., Vanda,s President and ... 2017 milestones underscores Vanda,s commitment to bringing important ...
(Date:2/15/2017)... 15, 2017 Windtree Therapeutics, Inc. (Nasdaq: ... aerosolized KL4 surfactant therapies for respiratory diseases, will host ... at 8:00 AM EST on Thursday, February 16, 2017 ... program, the recently announced closing of a $10.5 million ... To participate in the live call and take ...
(Date:2/15/2017)... ... 2017 , ... Diameter Health (Diameter) and Lantana ... in the hands of Lantana analysts. The high-performance platform of Diameter combined with ... entities – all those mining value from clinical data – to get the ...
Breaking Biology Technology:
(Date:2/2/2017)... Feb. 1, 2017  Central to its deep ... advances worldwide, The Japan Prize Foundation today announced ... have pushed the envelope in their respective fields ... Three scientists are being recognized with the 2017 ... not only contribute to the advancement of science ...
(Date:1/31/2017)... , Jan. 31, 2017  Spero Therapeutics, LLC, ... for the treatment of bacterial infections, today announced ... antibacterial candidates from Pro Bono Bio Ltd (PBB) ... of multi-drug resistant forms of Gram-negative bacteria.   The ... Infectives Ltd, a PBB group company. ...
(Date:1/26/2017)...  Crossmatch, a leading provider of security and identity ... combatting fraud, waste and abuse in assistance operations around ... on Disaster Relief conference in Panama City ... and foreign assistance organizations throughout Latin America ... a largely unacknowledged problem in the foreign assistance and ...
Breaking Biology News(10 mins):